Abstract
Several cross-sectional studies have reported a relationship between elevated serum activity of liver enzymes [e.g. alanine aminotransferase (ALT) and gamma-glutamyltransferase (γGT)] and metabolic syndrome (MetS) and/or diabetes mellitus (DM). Raised serum activity of liver enzymes independently predicted the future development of MetS and DM as well as cardiovascular (CV) events and/or total/CV mortality in prospective studies. However, this association was not consistently demonstrated and it appears to be independent of alcohol intake. Even though these associations can be partly attributed to non-alcoholic fatty liver disease (NAFLD) and insulin resistance, there may be additional underlying mechanisms that contribute to the increased CV risk (e.g. inflammation and oxidative stress). The association of γGT with atherosclerotic plaque is of particular importance. The present review considers the link between serum liver enzyme activities and vascular risk. The links with DM and MetS are also discussed.
Keywords: Liver enzyme, alanine aminotransferase, gamma-glutamyltransferase, aspartate aminotransferase, non-alcoholic fatty liver disease, cardiovascular disease, cardiovascular risk, metabolic syndrome, diabetes mellitus, atherosclerotic plaque
Current Pharmaceutical Design
Title: Liver Enzymes: Potential Cardiovascular Risk Markers?
Volume: 17 Issue: 33
Author(s): Eirini Lioudaki, Emmanuel S. Ganotakis and Dimitri P. Mikhailidis
Affiliation:
Keywords: Liver enzyme, alanine aminotransferase, gamma-glutamyltransferase, aspartate aminotransferase, non-alcoholic fatty liver disease, cardiovascular disease, cardiovascular risk, metabolic syndrome, diabetes mellitus, atherosclerotic plaque
Abstract: Several cross-sectional studies have reported a relationship between elevated serum activity of liver enzymes [e.g. alanine aminotransferase (ALT) and gamma-glutamyltransferase (γGT)] and metabolic syndrome (MetS) and/or diabetes mellitus (DM). Raised serum activity of liver enzymes independently predicted the future development of MetS and DM as well as cardiovascular (CV) events and/or total/CV mortality in prospective studies. However, this association was not consistently demonstrated and it appears to be independent of alcohol intake. Even though these associations can be partly attributed to non-alcoholic fatty liver disease (NAFLD) and insulin resistance, there may be additional underlying mechanisms that contribute to the increased CV risk (e.g. inflammation and oxidative stress). The association of γGT with atherosclerotic plaque is of particular importance. The present review considers the link between serum liver enzyme activities and vascular risk. The links with DM and MetS are also discussed.
Export Options
About this article
Cite this article as:
Lioudaki Eirini, S. Ganotakis Emmanuel and P. Mikhailidis Dimitri, Liver Enzymes: Potential Cardiovascular Risk Markers?, Current Pharmaceutical Design 2011; 17 (33) . https://dx.doi.org/10.2174/138161211798220945
DOI https://dx.doi.org/10.2174/138161211798220945 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Type 2 Diabetes Mellitus and Invokana: An FDA Approved Drug
Current Diabetes Reviews Role of Renin Angiotensin System Inhibitors in Cardiovascular and Renal Protection: A Lesson from Clinical Trials
Current Pharmaceutical Design Oxidative Stress in the Pathogenesis/Treatment of Atherosclerosis
Current Nutrition & Food Science An Overview of Innovations in Analysis and Beneficial Health Effects of Wine Polyphenols
Mini-Reviews in Medicinal Chemistry Recent Developments on Endothelin Antagonists as Immunomodulatory Drugs - from Infection to Transplantation Medicine
Recent Patents on Cardiovascular Drug Discovery Phenotypes and Enviromental Factors: Their Influence in PCOS
Current Pharmaceutical Design Early-life Programming of Type 2 Diabetes Mellitus: Understanding the Association between Epigenetics/Genetics and Environmental Factors
Current Genomics Diabetes Case Identification Methods Applied to Electronic Medical Record Systems: Their Use in HIV-Infected Patients
Current HIV Research Investigation of the Metabolism of Rufinamide and Its Interaction with Valproate
Drug Metabolism Letters Acetylome Regulation by Sirtuins in the Brain: From Normal Physiology to Aging and Pathology
Current Pharmaceutical Design Apoptosis: A Key in Neurodegenerative Disorders
Current Neurovascular Research Can Life Before Birth Affect Health Ever After?
Current Women`s Health Reviews Recent Research Progress in Natural Bioactive Constituents against Lipid Metabolic Diseases
Current Topics in Medicinal Chemistry Anagliptin, A Dipeptidyl Peptidase-4 Inhibitor Ameliorates Arterial Stiffness in Association with Reduction of Remnant-Like Particle Cholesterol and Alanine Transaminase Levels in Type 2 Diabetic Patients
Current Vascular Pharmacology Cardiotonic Steroids in Adaptation to Dietary Salt Intake
Current Clinical Pharmacology Degludec: A Novel Basal Insulin
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Genetics and Genomics Interventions for Promoting Millets as Functional Foods
Current Genomics Conventional and Alternative Treatment Options for Allergic Rhinitis
Current Respiratory Medicine Reviews Pancreas Development and β-Cell Differentiation of Embryonic Stem Cells
Current Medicinal Chemistry Evaluation of Antidiabetic Activity of <i>Rosmarinus officinalis var. prostratus</i> Growing in Syria in Alloxan Diabetic Rats
Current Bioactive Compounds